PON3

Across TCGA pan-cancer cohorts, PON3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PON3 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PON3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PON3 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, PDAC, and LUAD are the cancer types where PON3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.532	0.240	.004	20	view →
PDAC	OS	Quartile	All	0.383	0.728	.026	11	view →
LUAD	OS	Quartile	III,IV	0.839	0.250	.030	4	view →
HNSC	OS	Median	IV	0.725	0.948	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PON3–GBM (DFS)

Open the GBM breakdown →